Iran Cancer Statistics in 2012 and Projection of Cancer Incidence by 2035

  • Elham Mohebbi Cancer Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
  • Azin Nahvijou Cancer Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Maryam Hadji Cancer Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Hamideh Rashidian Cancer Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Monireh Sadat Seyyedsalehi Cancer Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Saeed Nemati Cancer Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohammad Reza Rouhollahi Cancer Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Kazem Zendehdel Cancer Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Keywords: Neoplasm, Iran, Prevalence, Incidence, Mortality, GLOBOCAN


Background: Burden of cancer is increasing worldwide, especially in the low and middle income countries (LMICs), including Iran. Several reports have been published about cancer statistics in Iran, although they had shortcomings and provided variable results. We reported the most valid cancer statistics about Iran.Methods: We used Globocan database and reported age standardize incidence rate (ASR), mortality rate (ASMR), and five-year prevalence of cancer in Iran in 2012, and compared it with the results of 2008. We also provided the projection of cancer incidence for 2035 and estimated the life time cancer risks by age 75. Results: ASRs per 100,000 were 134.7 for men and 120.1 for women. The most common cancers were breast (ASR 28.1), colorectal (ASR 10.5), stomach (ASR 9.7) cancers in women and stomach (ASR 20.6), bladder (ASR 13.2), prostate (ASR 12.6) cancers in men. The ASR was about 19% higher in 2012 (127.7/100,000) compared to 2008 (107.3/100,000). ASR of all cancer sites will increase about 2.17 times by 2035. ASMR was about 20% higher in men (90.4/100,000) than women (72.7/100,000) in 2012. The highest ASMRs was observed for breast cancer (9.9/100,000) in women and stomach cancer (17.3/100,000) in men. Five-year prevalence of all cancers was 79,194 for men and 90,521 for women in 2012. Lifetime risk of occurrence of all types of cancer was 25%. In other words, 1 in 4 Iranian people will be diagnosed with cancer before the age of 75 years. Conclusion: Stomach and breast cancers were the most common cancers in Iranian men and women, respectively. Iran and other LMICs will experience major increase in the incidence and mortality of cancer in the next decades. They need to collocate further resources for cancer surveillance system and monitor the cancer statistics for evidence based cancer control program.


Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013. JAMA oncology. 2015;1(4):505-27.

Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. The lancet oncology. 2012;13(8):790-801.

Fitzmaurice C. Burden of cancer in the Eastern Mediterranean Region, 2005–2015: findings from the Global Burden of Disease 2015 Study. International Journal of Public Health. 2017:1-14.

Global burden of Diseases. Washington: Institute of Health Metric and Evaluation; 2014 [cited 2016 3 September]. Available from:

National Cancer Registry Report. Tehran, Iran: Ministry of Health and Medical Education, 2010.

National Cancer Registry Report. Tehran, Iran: Ministry of Health and Medical Education, 2011.

Malekzadeh R, Mohebbi E, Zendehdel K. Underestimation of Cancer Incidence in Iran and Necessity for Establishing Population-Based Cancer Registries. European Journal of Cancer Care. 2018;27(1).

Zendehdel K, Sedighi Z, Hasanlou Z, Nahvijou A. Improving quality of cancer registration in Iran. Part1: evaluation and comparison of cancer registration results in the country. Mirror of Heritage. 2010;12(4):42-9.

Zendehdel K, Hasanlou Z, Sedighi Z, Nahvijou A, Mousavi Jarrahi S, Malekzadeh R, et al. Improving quality of cancer registration in iran. Part2: Suggesting new national cancer registration program in iran, based on comparative study of 18 countries. Mirror of Heritage 2010;12(4):50-7.

Zendehdel K, Sedighi Z, Hassanloo J, Nahvijou A. Audit of a nationwide pathology-based cancer registry in Iran. Basic & Clinical Cancer Research. 2016;3(2):7-13.

GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012: Interantional Agengy on Cancer Research; 2012 [cited 2017 15th December]. Available from:

Segi M, Fujisaku S, Kurihara M, Narai Y, Sasajima K. The age-adjusted death rates for malignant neoplasms in some selected sites in 23 countries in 1954-1955 and their geographical correlation. The Tohoku journal of experimental medicine. 1960;72(1):91-103.

Doll R, Cook P. Summarizing indices for comparison of cancer incidence data. International journal of cancer. 1967;2(3):269-79.

Islamic Republic of Iran: Fast Stat Cancer. Lion, France: IARC, 2008.

International Human Development Indicators: United Nations Development Programme; 2017 [cited 2017 28 October 28 October ]. Available from:

Khosravi A, Najafi F, Rahbar M, Motlagh M, Kabir M. Health indicators (Simaye salaamat) of Islamic Republic of Iran Tehran, Iran: Ministry of Health and Medical Education, 2009.

Sasieni P, Shelton J, Ormiston-Smith N, Thomson C, Silcocks P. What is the lifetime risk of developing cancer?: the effect of adjusting for multiple primaries. British journal of cancer. 2011;105(3):460.

Population Pyramids of the World from 1950 to 2100 [cited 2017 28 October]. Available from:

Ghiasvand R, Adami H-O, Harirchi I, Akrami R, Zendehdel K. Higher incidence of premenopausal breast cancer in less developed countries; myth or truth? BMC cancer. 2014;14(1):343.

Delavari A, Bishehsari F, Salimzadeh H, Khosravi P, Delavari F, Nasseri-Moghaddam S, et al. Adenoma detection rates in an opportunistic screening colonoscopy program in Iran, a country with rising colorectal cancer incidence. BMC gastroenterology. 2014;14(1):196.

Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World journal of gastroenterology: WJG. 2014;20(20):6055.

Malekzadeh F, Sepanlou SG, Poustchi H, Naghavi M, Forouzanfar MH, Shahraz S, et al. Burden of Gastrointestinal and Liver Diseases in Iran: Estimates Based on the Global Burden of Disease, Injuries, and Risk Factors Study, 2010. Middle East journal of digestive diseases. 2015;7:138.

Abubakar I, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71.

Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA oncology. 2017;3(4):524-48.

Gyawali B, Shimokata T, Honda K, Tsukuura H, Ando Y. Should low-income countries invest in breast cancer screening? Cancer Causes & Control. 2016;27(11):1341-5.

Organization WH. WHO position paper on mammography screening: World Health Organization; 2014.

Ghiasvand R, Bahmanyar S, Zendehdel K, Tahmasebi S, Talei A, Adami H-O, et al. Postmenopausal breast cancer in Iran; risk factors and their population attributable fractions. BMC cancer. 2012;12(1):414.

Abbasi-Shavazi MJ, Lutz W, Hosseini-Chavoshi M, KC S. Education and the world's most rapid fertility decline in Iran. 2008.

Abbasi-Shavazi MJ, Hosseini-Chavoshi M, ter Mc Donald P. The Path to Be low Re place ment Fer til ity in the Is lamic Re pub lic of Iran. Asia-Pacific Population Journal. 2007;22(2):91.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5).

Ghiasvand R, Maram ES, Tahmasebi S, Tabatabaee SHR. Risk factors for breast cancer among young women in southern Iran. International journal of cancer. 2011;129(6):1443-9.

Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: Results of a population‐based Cancer Registry from Iran. International journal of cancer. 2003;107(1):113-8.

Sajaddi A, Nouraie M, Mohagheghi M, Mousavi-Jarrahi A, Malekezadeh R, Parkin D. Cancer occurrence in Iran in 2002, an international perspective. Asian Pacific journal of cancer prevention. 2005;6(3):359.

Mohagheghi S, Mousavi Jarrahi S, Malekzadeh R, Parkin M. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998–2001. 2009.

Marzban M, Nahvijou A, Jafari N. Six-fold difference in the stomach cancer mortality rate between northern and southern Iran. Archives of Iranian medicine. 2012;15(12):741.

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. New England Journal of Medicine. 2001;345(11):784-9.

Sipponen P, Hyvärinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scandinavian Journal of Gastroenterology. 1993;28(sup196):3-6.

Tsugane S. Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer science. 2005;96(1):1-6.

Pourfarzi F, Whelan A, Kaldor J, Malekzadeh R. The role of diet and other environmental factors in the causation of gastric cancer in Iran—a population based study. International journal of cancer. 2009;125(8):1953-60.

Campbell PT, Sloan M, Kreiger N. Dietary patterns and risk of incident gastric adenocarcinoma. American journal of epidemiology. 2007;167(3):295-304.

Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. The American journal of clinical nutrition. 2003;78(3):559S-69S.

Sjödahl K, Lu Y, Nilsen TI, Ye W, Hveem K, Vatten L, et al. Smoking and alcohol drinking in relation to risk of gastric cancer: A population‐based, prospective cohort study. International journal of cancer. 2007;120(1):128-32.

La Torre G, Chiaradia G, Gianfagna F, De Lauretis A, Boccia S, Mannocci A, et al. Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years. Tumori. 2009;95(1):13.

Kogevinas M, Pearce N, Susser M, Boffetta P. Social inequalities and cancer. Oxford: IARC 1997.

Leitzmann MF, Koebnick C, Freedman ND, Park Y, Ballard-Barbash R, Hollenbeck A, et al. Physical activity and esophageal and gastric carcinoma in a large prospective study. American journal of preventive medicine. 2009;36(2):112-9.

D’Elia L, Galletti F, Strazzullo P. Dietary salt intake and risk of gastric cancer. Advances in Nutrition and Cancer: Springer; 2014. p. 83-95.

Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. Journal of clinical epidemiology. 2003;56(1):1-9.

Kamali-Sarvestani E, Bazargani A, Masoudian M, Lankarani K, Taghavi A-R, Saberifiroozi M. Association of H pylori cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases. World journal of gastroenterology: WJG. 2006;12(32):5205.

Chen M-J, Wu D-C, Ko Y-C, Chiou Y-Y. Personal history and family history as a predictor of gastric cardiac adenocarcinoma risk: a case-control study in Taiwan. The American journal of gastroenterology. 2004;99(7):1250-7.

Correa P, Piazuelo MB. Natural history of Helicobacter pylori infection. Digestive and Liver Disease. 2008;40(7):490-6.

Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. 2009.

Møller H, Heseltine E, Vainio H. Working group report on schistosomes, liver flukes and Helicobacter pylori. Meeting held at IARC, Lyon, 7–14 June 1994. International Journal of Cancer. 1995;60(5):587-9.

Adami H-O, Hunter DJ, Trichopoulos D. Textbook of cancer epidemiology: Monographs in Epidemiology and; 2008.

McGuire S. World cancer report 2014. Geneva, Switzerland: World Health Organization, international agency for research on cancer, WHO Press, 2015. Advances in Nutrition: An International Review Journal. 2016;7(2):418-9.

Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. World journal of gastroenterology: WJG. 2014;20(38):13842.

Kato M, Asaka M. Recent development of gastric cancer prevention. Japanese journal of clinical oncology. 2012;42(11):987-94.

Rouhollahi MR, Mohagheghi MA, Mohammadrezai N, Motlagh AG, Harirchi I. Situation analysis of the National Comprehensive Cancer Control Program in the IR of Iran; assessment and recommendations based on the IAEA imPACT mission. Archives of Iranian medicine. 2014;17(4):222.

Klabunde C, Blom J, Bulliard J-L, Garcia M, Hagoel L, Mai V, et al. Participation rates for organized colorectal cancer screening programmes: an international comparison. Journal of medical screening. 2015;22(3):119-26.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010;60(5):277-300.

Nelson RL, Persky V, Turyk M. Determination of factors responsible for the declining incidence of colorectal cancer. Diseases of the colon & rectum. 1999;42(6):741-52.

Policy statement and recommended actions for early detection of colorectal cancer in the Eastern Mediterranean Region. World Health Organization, 2016.

Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016:gutjnl-2015-310912.

Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA: a cancer journal for clinicians. 2009;59(6):366-78.

Forman D, Bray F, Brewster D, Gombe M, Kohler B, Piñeros M, et al. Cancer incidence in five continents: IARC; 2013.

Nikfarjam Z, Massoudi T, Salehi M, Salehi M, Khoshroo F. Demographic survey of four thousand patients with 10 common cancers in North Eastern Iran over the past three decades. Asian Pac J Cancer Prev. 2014;15(23):10193-8.

Pakzad R, Mohammadian-Hafshejani A, Khosravi B, Soltani S, Pakzad I, Mohammadian M, et al. The incidence and mortality of esophageal cancer and their relationship to development in Asia. Annals of translational medicine. 2016;4(2).

Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. Bmj. 2009;338:b929.

Nasrollahzadeh D, Ye W, Shakeri R, Sotoudeh M, Merat S, Kamangar F, et al. Contact with ruminants is associated with esophageal squamous cell carcinoma risk. International journal of cancer. 2015;136(6):1468-74.

Shakeri R, Kamangar F, Nasrollahzadeh D, Nouraie M, Khademi H, Etemadi A, et al. Is opium a real risk factor for esophageal cancer or just a methodological artifact? Hospital and neighborhood controls in case-control studies. PloS one. 2012;7(3):e32711.

Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013 Feb 2;381(9864):400-12. PubMed PMID: 23374478. Epub 2013/02/05. eng.

Roshandel G, Merat S, Sotoudeh M, Khoshnia M, Poustchi H, Lao-Sirieix P, et al. Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. British journal of cancer. 2014;111(12):2235-41.

Afshari M, Janbabaei G, Bahrami MA, Moosazadeh M. Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer. PloS one. 2017;12(6):e0178527.

Ziaaddini H, Ziaaddini M. The household survey of drug abuse in Kerman, Iran. Journal of Applied Sciences. 2005;5:380-2.

Nikfarjam A, Shokoohi M, Shahesmaeili A, Haghdoost AA, Baneshi MR, Haji-Maghsoudi S, et al. National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran. International Journal of Drug Policy. 2016;31:147-52.

Gustafsson L, Pontén J, Bergstrôm R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. International Journal of Cancer. 1997;71(2):159-65.

Lăără E, Day N, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. The Lancet. 1987;329(8544):1247-9.

Khorasanizadeh F, Hassanloo J, Khaksar N, Taheri SM, Marzaban M, Rashidi BH, et al. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women—Analyses of national data and systematic review of the literature. Gynecologic oncology. 2013;128(2):277-81.

Nahvijou A, Daroudi R, Tahmasebi M, Hashemi FA, Hemami MR, Sari AA, et al. Cost-effectiveness of different cervical screening strategies in Islamic Republic of Iran: a middle-income country with a low incidence rate of cervical cancer. PloS one. 2016;11(6):e0156705.

Nahvijou A, Sari AA, Zendehdel K, Marnani AB. Management of precancerous cervical lesions in iran: a cost minimizing study. Asian Pac J Cancer Prev. 2014;15(19):8209.

Khatibi M, Rasekh HR, Shahverdi Z. Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran. Iranian journal of pharmaceutical research: IJPR. 2014;13(Suppl):225.

Eriksen M, Mackay J, Ross H. The tobacco atlas: American Cancer Society; 2013.

Nemati S, Rafei A, Freedman ND, Fotouhi A, Asgary F, Zendehdel K. Cigarette and Water-Pipe Use in Iran: Geographical Distribution and Time Trends among the Adult Population; A Pooled Analysis of National STEPS Surveys, 2006-2009. Archives of Iranian Medicine (AIM). 2017;20(5).

How to Cite
Mohebbi E, Nahvijou A, Hadji M, Rashidian H, Seyyedsalehi MS, Nemati S, Rouhollahi MR, Zendehdel K. Iran Cancer Statistics in 2012 and Projection of Cancer Incidence by 2035. BCCR. 9(3):3-2.
Original Articles